Northway Biotech, an end-to-end CDMO, and Kaida BioPharma (Kaida), an early-stage pharma company, have entered into a manufacturing agreement to produce Kaida’s KAD101. Per the agreement, Northway Biotech will leverage its expertise to develop a robust manufacturing process for KAD101.  This involves developing analytical methods, optimizing formulation, development, and scaling up of the production process, and manufacturing a cGMP drug substance batch for clinical studies. KAD101...